See the DrugPatentWatch profile for cosentyx

Reducing the dosage of Cosentyx, a medication used to treat several chronic inflammatory diseases such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, may pose certain risks.

Firstly, reducing the dosage without medical consultation could lead to a suboptimal therapeutic response. Cosentyx's active ingredient, secukinumab, works by inhibiting a specific protein involved in inflammation. Insufficient levels of secukinumab in the body might not effectively control inflammation, leading to a potential worsening of symptoms [1].

Secondly, abrupt discontinuation or sudden dosage reduction may increase the risk of disease flare-ups. This is because the body may not have enough time to adjust to the reduced levels of the medication, potentially leading to a sudden increase in inflammation [1].

Lastly, it's important to note that Cosentyx is subject to patent protection. As of 2021, Cosentyx is still under patent, meaning generic versions are not available in the market [2]. This could potentially lead to higher costs for patients if they need to increase their dosage back to the original amount.

In conclusion, reducing Cosentyx dosage without medical advice can lead to suboptimal therapeutic response, increased risk of disease flare-ups, and potential financial implications due to the patented status of the drug.

Sources:
[1] "Secukinumab (Cosentyx)." Mayo Clinic, Mayo Foundation for Medical Education and Research, 15 Jan. 2021, www.mayoclinic.org/drugs-supplements/secukinumab-cosentyx-subcutaneous-route/description/drg-20168553.
[2] "Secukinumab." DrugPatentWatch, DrugPatentWatch, 2021, www.drugpatentwatch.com/drugs/secukinumab.